{"links":{"html":"https://www.erudio.com/reports/ideate-lung01-nct05280470","json":"https://www.erudio.com/reports/ideate-lung01-nct05280470.json","markdown":"https://www.erudio.com/reports/ideate-lung01-nct05280470.md","mcp":{"server":"https://mcp.erudio.com/mcp","tool":"get_report_card","arguments":{"slug":"ideate-lung01-05280470"}},"request":"https://www.erudio.com/contact?report=ideate-lung01-05280470"},"offer":{"cited_commentary_sources":54,"verified_hcp_statements":248,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI. For scientific and insight use inside the organization, not for promotional targeting or outreach. Every report already names and describes its speakers.","available_with":"12-month updates","cap_usd":1250,"identity_verified_people":29,"optional":true,"price_per_verified_person_usd":15,"price_usd":435,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":1250,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_tools":["create_order","get_order","recover_key"],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"ideate-lung01-nct05280470"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=ideate-lung01-05280470","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/ideate-lung01-nct05280470","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"standard","size_rule":"Standard: 151–300 verified statements","updates_usd":{"3_months":2200,"6_months":3100,"12_months":4400},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-20T08:15:03.901130Z","notify_subscribers":false,"status":"new","summary":{"reason":"Initial accepted edition has no weekly change log.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":12,"no_commentary_found":0},"aspects":[{"claim_count":13,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":13,"title":"Primary endpoint: Percentage of Participants With Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) Following Treatment With I-DXd in Participants With Pretreated ES-SCLC"},{"claim_count":11,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.secondaryOutcomes","source_count":12,"title":"Secondary endpoints"},{"claim_count":12,"coverage":"discussed","id":"T3","registry_field":"conditionsModule","source_count":8,"title":"Population and setting"},{"claim_count":6,"coverage":"discussed","id":"T4","registry_field":"armsInterventionsModule.armGroups","source_count":4,"title":"The comparison"},{"claim_count":24,"coverage":"discussed","id":"T5","registry_field":"outcomesModule","source_count":4,"title":"Safety and tolerability"},{"claim_count":7,"coverage":"discussed","id":"T6","registry_field":"designModule","source_count":2,"title":"Design and conduct"},{"claim_count":23,"coverage":"discussed","id":"A1","source_count":6,"title":"CNS activity, subgroup interpretation and local-treatment implications"},{"claim_count":16,"coverage":"discussed","id":"A2","source_count":3,"title":"Pulmonary work-up, monitoring and treatment redirection"},{"claim_count":20,"coverage":"discussed","id":"A3","source_count":8,"title":"Comparative confirmation and interpretation of regulatory events"},{"claim_count":35,"coverage":"discussed","id":"A4","source_count":7,"title":"Sequencing, access, patient fitness and trial discussions"},{"claim_count":33,"coverage":"discussed","id":"A5","source_count":11,"title":"Target rationale, biomarkers and differentiation among ADCs"},{"claim_count":8,"coverage":"discussed","id":"A6","source_count":4,"title":"Combination rationale and unresolved resistance"}],"counts":{"cited_sources":55,"claims_by_expression_type":{"comparison":30,"experience":12,"interpretation":34,"opinion":34,"primary_context":2,"question":23,"restatement":35,"uncertainty":23,"unspecified":55},"claims_by_kind":{"attributed_opinion":25,"counterview":2,"interpretation":16,"limitation":7,"source_observation":198},"clinician_statements":61,"evidence_units":195,"findings":8,"people_cited":39,"people_identity_verified":29,"people_total":40,"screened_sources":80,"verified_claims":248},"depth":"rich","findings_index":[{"id":"F1","structure":{"claims":17,"claims_by_group":{"comparisons":0,"experience":3,"questions":5,"restated":2,"views":7},"has_counterview":true,"limitations":3,"links":{"context":8,"support":18},"ma_question":true,"named_voices":5,"passages":18,"sources":3,"sources_by_kind":{"media":3}},"title":"ILD raises patient-selection and stopping questions—not a blanket exclusion for poor pulmonary function"},{"id":"F2","structure":{"claims":32,"claims_by_group":{"comparisons":6,"experience":2,"questions":1,"restated":13,"views":10},"has_counterview":true,"limitations":3,"links":{"context":6,"support":42},"ma_question":true,"named_voices":18,"passages":29,"sources":21,"sources_by_kind":{"commentary":16,"media":5}},"title":"Response enthusiasm does not resolve durability, survival or the dose trade-off"},{"id":"F3","structure":{"claims":22,"claims_by_group":{"comparisons":1,"experience":1,"questions":4,"restated":9,"views":7},"has_counterview":true,"limitations":3,"links":{"context":4,"support":29},"ma_question":true,"named_voices":13,"passages":16,"sources":9,"sources_by_kind":{"commentary":6,"media":3}},"title":"The filing-withdrawal discussion sharpens the need for comparative evidence, but does not establish the FDA's reasoning"},{"id":"F4","structure":{"claims":25,"claims_by_group":{"comparisons":4,"experience":0,"questions":1,"restated":14,"views":6},"has_counterview":true,"limitations":4,"links":{"context":16,"support":29},"ma_question":true,"named_voices":6,"passages":18,"sources":6,"sources_by_kind":{"commentary":2,"media":4}},"title":"CNS activity is clinically compelling to speakers, but protection and treatment substitution remain unproven"},{"id":"F5","structure":{"claims":36,"claims_by_group":{"comparisons":1,"experience":4,"questions":12,"restated":3,"views":16},"has_counterview":true,"limitations":5,"links":{"context":16,"support":42},"ma_question":true,"named_voices":12,"passages":31,"sources":8,"sources_by_kind":{"commentary":5,"media":3}},"title":"Placement depends on prior tarlatamab, access, performance status and feasible alternatives"},{"id":"F6","structure":{"claims":22,"claims_by_group":{"comparisons":4,"experience":1,"questions":6,"restated":7,"views":4},"has_counterview":true,"limitations":3,"links":{"context":10,"support":25},"ma_question":true,"named_voices":7,"passages":25,"sources":6,"sources_by_kind":{"commentary":1,"media":5}},"title":"Chemotherapy-like familiarity supports adoption, but does not mean low toxicity"},{"id":"F7","structure":{"claims":33,"claims_by_group":{"comparisons":8,"experience":0,"questions":5,"restated":10,"views":10},"has_counterview":true,"limitations":4,"links":{"context":17,"support":39},"ma_question":true,"named_voices":12,"passages":33,"sources":11,"sources_by_kind":{"commentary":7,"media":4}},"title":"A credible target does not yet identify the preferred ADC or a selection biomarker"},{"id":"F8","structure":{"claims":8,"claims_by_group":{"comparisons":1,"experience":0,"questions":3,"restated":0,"views":4},"has_counterview":false,"limitations":2,"links":{"context":2,"support":8},"ma_question":true,"named_voices":5,"passages":9,"sources":4,"sources_by_kind":{"commentary":1,"media":3}},"title":"Combination optimism is a research rationale, not evidence for adding treatment"}],"medical_affairs_question":"How should education distinguish risk-based redirection, closer observation, diagnostic uncertainty and trial-specific stopping rules?","sections":{"analysis":[{"id":"section-1","level":2,"title":"ILD: distinguish risk, recognition, severity and treatment interruption"},{"id":"section-2","level":2,"title":"Response enthusiasm versus the durability and survival question"},{"id":"section-3","level":2,"title":"Comparative confirmation and the reported filing outcome"},{"id":"section-4","level":2,"title":"CNS findings: clinical relevance without a prevention or local-treatment claim"},{"id":"section-5","level":2,"title":"Sequencing and access: conditional pathways, not one agreed algorithm"},{"id":"section-6","level":2,"title":"Familiar toxicities and patient communication"},{"id":"section-7","level":2,"title":"Target rationale, biomarkers and competition"},{"id":"section-8","level":2,"title":"Combinations: distinguish biologic promise from established addition"},{"id":"section-9","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase2","trial_dimensions":[{"findings":[{"id":"F2","shared_claims":13},{"id":"F3","shared_claims":1}],"id":"T1","label":"Primary endpoint: Percentage of Participants With Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) Following Treatment With I-DXd in Participants With Pretreated ES-SCLC"},{"findings":[{"id":"F2","shared_claims":10},{"id":"F6","shared_claims":2}],"id":"T2","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":4},{"id":"F4","shared_claims":1},{"id":"F5","shared_claims":8},{"id":"F6","shared_claims":1}],"id":"T3","label":"Population and setting"},{"findings":[{"id":"F2","shared_claims":6}],"id":"T4","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":13},{"id":"F2","shared_claims":2},{"id":"F5","shared_claims":1},{"id":"F6","shared_claims":11}],"id":"T5","label":"Safety and tolerability"},{"findings":[{"id":"F2","shared_claims":4},{"id":"F3","shared_claims":1},{"id":"F4","shared_claims":2},{"id":"F5","shared_claims":1}],"id":"T6","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-10-20T08:15:03.901130Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-20T08:24:03Z","record_hash":"ab36182f7c1224cccccd030d28acdb45473fb638448f00f747976b2b718837cc","release_hash":"bdc462dd7e41d9d9901cb2abfa66e086300797ba42d5e2ea31aa7c6d0a8ec517","report_id":"erudio-nct05280470","run_id":"e655402f-0b05-47f9-811a-0e955688e33e","schema_version":"5.0","slug":"ideate-lung01-05280470","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"IDeate-Lung01 asks whether ifinatamab deruxtecan can shrink tumors in previously treated extensive-stage small-cell lung cancer. Clinicians in the sources reviewed for this edition question how response enthusiasm should shape treatment placement, which remains conditional. They welcome intracranial activity while raising concerns about response durability and chemotherapy-like toxicity. Their commentary leaves comparative benefit unresolved and does not establish the reasons for the filing withdrawal.","meta_description":"80 sources screened · 248 verified statements (61 from speakers with a confirmed clinical role) from 55 sources · 8 findings. Updated Oct 20, 2026.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-07be18b48d754e4eb92f"],"id":"F4","paraphrase":"In a YouTube discussion, a speaker asked whether I-DXd or other B7-H3 antibody-drug conjugates had been studied for activity in brain metastases.","publication_caveats":{"reason":"Publication caveats are not specified for this source in the sources reviewed for this edition.","status":"not_set"},"source_channel":"youtube","source_date":"2026-09-10","title":"CNS activity is clinically compelling to speakers, but protection and treatment substitution remain unproven"},{"cited_claim_ids":["claim-57024006909a2ab2a42e"],"id":"F3","paraphrase":"An X-thread contributor asked whether interstitial lung disease was a factor in withdrawal of the I-DXd application.","publication_caveats":{"reason":"Publication caveats are not specified for this source in the sources reviewed for this edition.","status":"not_set"},"source_channel":"x_thread","source_date":"2026-09-25","title":"The filing-withdrawal discussion sharpens the need for comparative evidence, but does not establish the FDA's reasoning"}]},"publication":{"approved_at":"2026-10-20T08:24:03Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":80},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","For 1 recording, a transcript separated by speaker was not available, so quotes come from the original automatic transcript and may lack speaker labels.","Some clinician views in the sources used in this report are not yet captured as evidence in this edition; the next refresh takes them up.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","Out of scope: 3 passages in the reviewed sources discuss other trials or topics outside this report's scope; they are not part of this edition.","212 statements in the sources reviewed for this edition discuss other treatment settings or topics unrelated to this trial's question and are not included.","Further source limits apply, so some matching discussion may be missing.","The sources reviewed for this edition do not represent all HCP discussion, and repeated posts or shared presentations cannot be counted as independent clinician agreement.","Searches emphasized trial identifiers, drug names and selected relapsed-disease terms. Unnamed references and transcription variants may be absent; eight additional sources were not read, and several passages in included discussions were not fully evaluated.","Some participants could not be identified reliably, and one recording relied on its available transcript. Anonymous views have not been assigned to faculty from a program listing, a host's address or an account identifier.","The unidentified long-form X author's clinical role is unknown. The author's regulatory and comparative arguments should not be treated as physician consensus or an FDA explanation.","The discussion spans different studies, analyses and dates. Earlier Phase I/II findings, IDeate-Lung01 interim and later reports, and IDeate-Lung02 plans cannot be combined as one dataset or used to infer a change of mind.","Reported efficacy and safety values differ across sources. These differences were preserved rather than reconciled, pooled or converted into treatment comparisons; Ergün's post does not specify an OS unit.","The complete protocol and an exact approved I-DXd label were not available. Source reports of regulatory developments, trial management and anticipated access do not establish current prescribing instructions or availability.","The eligibility described by Hann included ECOG 0–1 and treated or untreated asymptomatic brain metastases. The discussion does not establish applicability to poorer performance status or symptomatic CNS disease.","A case-discussion turn used 1 mg/kg for tarlatamab and a later turn used 1 mg. These were tentative, patient-specific statements, not reconciled dosing guidance."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":5,"other":0,"podcast":2,"publication":1,"registry":0,"regulatory":0,"x_thread":43,"x_video":0,"youtube":4},"by_evidence_role":{"commentary":54,"results":1},"count":55,"evidence_window":{"end":"2026-10-08","start":"2023-04-27"},"retrieval_snapshot":"2026-10-19T21:50:54.288911Z","timeline":[{"count":1,"week":"2023-W17"},{"count":3,"week":"2023-W36"},{"count":1,"week":"2023-W37"},{"count":1,"week":"2023-W50"},{"count":1,"week":"2024-W01"},{"count":1,"week":"2024-W16"},{"count":1,"week":"2024-W33"},{"count":4,"week":"2024-W36"},{"count":1,"week":"2024-W37"},{"count":1,"week":"2025-W09"},{"count":1,"week":"2025-W10"},{"count":1,"week":"2025-W17"},{"count":1,"week":"2025-W34"},{"count":1,"week":"2025-W35"},{"count":2,"week":"2025-W36"},{"count":3,"week":"2025-W37"},{"count":2,"week":"2025-W39"},{"count":8,"week":"2025-W42"},{"count":3,"week":"2025-W48"},{"count":1,"week":"2025-W49"},{"count":1,"week":"2026-W04"},{"count":2,"week":"2026-W05"},{"count":1,"week":"2026-W06"},{"count":1,"week":"2026-W08"},{"count":1,"week":"2026-W20"},{"count":1,"week":"2026-W24"},{"count":1,"week":"2026-W32"},{"count":1,"week":"2026-W36"},{"count":2,"week":"2026-W37"},{"count":1,"week":"2026-W38"},{"count":5,"week":"2026-W39"},{"count":1,"week":"2026-W40"},{"count":1,"week":"2026-W41"}],"undated_sources":1},"quote_policies":[{"id":"clinicaltrials:NCT05280470:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT05280470:context","quote_policy":"short_quote_link_out"},{"id":"pubmed:41086386","quote_policy":"no_derivatives"},{"id":"mcp:bluesky_thread:plc-3fjamuvrp7vadx7ck4uumxgc-3lwpaarnsts2n","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-7ni6ktnv7pnp3pk6eosdznrg-3lwtridxrsb24","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-b6or56vkmhywvtt2wkcsnbsc-3m3khq7lahs2i","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-b6or56vkmhywvtt2wkcsnbsc-3mwfdikkv2c2j","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-bxzk4m7k4l4pqhhbb3guu3qx-3lxcolidp3g2d","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-bxzk4m7k4l4pqhhbb3guu3qx-3lzllzxdgp62f","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-c2yxfgfn4dqg3scfkjo22okt-3mdur6ekisk22","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-ffhfzwr3igtwt4y7zdompvjv-3lwoamwpc6l2x","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-ffhfzwr3igtwt4y7zdompvjv-3lyawjiys5d2k","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-irxdqpoxqzotqwmfjj4u7pg6-3lyaymwv2og2o","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-o6ggjvnj4ze3mnrpnv5oravg-3lybdksjqkd2a","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-o6ggjvnj4ze3mnrpnv5oravg-3m3uhbtqa6j2c","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-ryo5z53ggbjijxq7nd6ftqjx-3m3cxqyed5c2a","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:21ea83","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:c2ba4b","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:f846a3","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:fe5fb0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1642210529505693698:4b1eebce-1da1-46b9-a7e5-1e5c418d0345","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1651717117400563712:d89b0be9-582b-4768-8a2f-1a2cc3834ed9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1665069760227287042:7fbc8bd2-2051-449a-a8ae-2436258d8360","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1700773298391728583:f586e671-5e94-4438-80a7-6c2836102d52","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1700773828539080810:6f9f18a7-cdab-4f66-82c7-c9bc6045dd7a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1700775461549388221:a971d5c9-5f92-40af-8ac9-a542ac6fa21c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1705137473582489699:8954e86a-d0cf-4bb6-babb-6e0faa11eb3e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1743101757020946823:39a7ebed-bafd-4554-929a-26df72a7eae9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1748834514065899639:8d26f552-7c26-4e30-a2b1-138ef3050978","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1781349570603041138:00f7be2d-cde7-4ed3-b889-6de976077277","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1800864596108230918:a77714fb-80c4-454e-94ee-3842432f0b44","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1823728788800462987:7ac79e44-bd0a-4c20-9264-c70b8bd4a759","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1832447691315646869:3540139f-26b7-4d57-8a35-ab5852e58023","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1832458790006067461:c2dad043-b6a0-4195-bd93-f82c61cb90df","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1832603250060562878:911227c3-6df2-4e01-b3cb-3a8dc7692393","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1832889715332415582:a74cc2b9-d6e8-4d24-bd68-956599f2dd73","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1832891142645399700:4bfb956b-cb61-4751-94c2-8be450d35438","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1833967034524156075:cb46a492-21bd-425b-88ec-d00b9c81f374","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1842164709639827563:9a43b2bf-1d10-46ed-bb2c-61a3189785e9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1885392078345007203:f52f233c-ebcd-4c84-925f-07618bffb6ae","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1894719061159776345:9269c540-9068-4a11-9718-990a2d1eacce","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1897257953742479599:19f710a7-b359-4dd5-8f8e-204c5a602301","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1916024345752711217:75ff13b1-9b7c-46f1-af9b-6005d758bee1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1928589298598568367:b566aad0-d628-4cf0-8150-435417cda958","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1955985259084071152:fc4fbedc-cbed-4213-a561-607ee7110ea8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1964739857605120297:41cf934e-93ba-4eed-aaf5-8809181bfded","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1964741221135400997:12d3aaea-1062-4ce3-97df-d83fbb2873ad","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1965735839918698780:ce721d9e-57ab-4b1b-8364-d00d50b7b9d7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1966138962998923557:7480921d-8f38-4b82-bd7f-e249cfe84d3b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1971196033159123110:31c6a3ad-cdf6-4435-b86e-139399849264","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1972035439742845002:9ab8dacd-d9d8-4661-b638-6e44f3c4b5d6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1978317428993012002:260928ac-d3d8-4df0-ab87-f758fee59e03","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1978807822965002297:493538b6-a47f-4632-aef0-b0670dc73473","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979569585339719737:ef1790e1-d3c9-4a06-aade-d67676684c68","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979573055451254938:b6a901b2-4efb-4365-bae6-d3eb81aaf0fa","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979574135044080102:5e9cbea1-e77d-4013-863c-133e6fea28d5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979574634837315899:6a7a24df-ce88-4cb9-a639-c4cce8db1521","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1995172054316834851:2db7b05c-774e-4d15-876d-3461b6b51df1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1995172121375293644:d9a4e974-1a22-4fc1-a9b0-4c7d72744773","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1995249405998637454:5652ecef-cc55-445c-b4f0-a3d4f490d3e2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2014792627749527647:41244a32-a0bf-4323-bfc2-6b4fd4b8f4c4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2017355753359548454:97bd91eb-96b6-484b-9f4c-557ab4cbd4c4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2018042601476108561:0b848235-4543-4ce0-bd1c-644ab9fbfac0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2018384244511211566:26b65369-f698-4df8-b9ea-1d6d499a6076","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2024531248929264108:4dedef1e-1aa7-4b30-9c2a-d77ddbc4f593","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2042676525539991908:096bffad-1b33-4415-9c86-7b429270fbab","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2084991027610296668:8a329dd4-59a3-4769-aa4d-be3df610324b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2096233353527566699:42b0a2c4-1167-4e8c-99bf-fe01d830fe06","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2098931042480738336:188b865c-555b-4dfb-aa9d-5b708095b69f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2098933006279102851:0d552003-3c8a-42a9-a198-7172036d5629","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2099798922684170750:d48cda7b-db85-447e-adc5-5ca52bb02c64","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2103593203945378208:72aa5798-5396-495b-ab5e-8841f9a8c6a6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2103626401861517784:e722a98e-f8ae-4463-953e-e4754d15b48f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2103633461030645778:ffe908c3-1f1c-4165-9fe2-e5861cf45d41","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2103713455148802116:016afa16-92cb-43f6-ad84-83dd60d2e696","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2104906915553915013:89e26ecf-3681-43d6-9205-8ef499ffe9fa","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107979303090831374:9043aede-a36d-470b-bdec-f22edf8e70b1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2110690839106044388:d29fecb5-206c-4ed7-a87b-63425cb91d68","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:SE92TltH-Uw","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:TSk2gVEwAhw","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:Y_cFhNbeN8U","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:dufZWxyRAYI","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:iJ0m-IJom0c","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":13,"other":0,"podcast":4,"publication":0,"registry":0,"regulatory":0,"x_thread":58,"x_video":0,"youtube":5},"by_evidence_role":{"commentary":80},"count":80,"evidence_window":{"end":"2026-10-16","start":"2023-04-01"},"retrieval_snapshot":"2026-10-19T21:50:54.288911Z","timeline":[{"count":1,"week":"2023-W13"},{"count":1,"week":"2023-W17"},{"count":1,"week":"2023-W22"},{"count":3,"week":"2023-W36"},{"count":1,"week":"2023-W37"},{"count":1,"week":"2023-W38"},{"count":1,"week":"2023-W43"},{"count":1,"week":"2023-W50"},{"count":1,"week":"2024-W01"},{"count":1,"week":"2024-W03"},{"count":1,"week":"2024-W16"},{"count":1,"week":"2024-W24"},{"count":1,"week":"2024-W26"},{"count":1,"week":"2024-W33"},{"count":5,"week":"2024-W36"},{"count":1,"week":"2024-W37"},{"count":1,"week":"2024-W40"},{"count":1,"week":"2024-W51"},{"count":1,"week":"2025-W05"},{"count":1,"week":"2025-W09"},{"count":1,"week":"2025-W10"},{"count":2,"week":"2025-W17"},{"count":1,"week":"2025-W22"},{"count":1,"week":"2025-W31"},{"count":1,"week":"2025-W33"},{"count":4,"week":"2025-W34"},{"count":1,"week":"2025-W35"},{"count":5,"week":"2025-W36"},{"count":3,"week":"2025-W37"},{"count":3,"week":"2025-W39"},{"count":8,"week":"2025-W42"},{"count":1,"week":"2025-W43"},{"count":3,"week":"2025-W48"},{"count":1,"week":"2025-W49"},{"count":1,"week":"2026-W04"},{"count":2,"week":"2026-W05"},{"count":2,"week":"2026-W06"},{"count":1,"week":"2026-W08"},{"count":1,"week":"2026-W15"},{"count":1,"week":"2026-W20"},{"count":1,"week":"2026-W24"},{"count":1,"week":"2026-W32"},{"count":1,"week":"2026-W36"},{"count":3,"week":"2026-W37"},{"count":1,"week":"2026-W38"},{"count":5,"week":"2026-W39"},{"count":1,"week":"2026-W40"},{"count":1,"week":"2026-W41"},{"count":1,"week":"2026-W42"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"reason":"Unmapped registry intervention: ifinatamab deruxtecan (i-dxd)","status":"unmapped"}],"indications":[{"reason":"Unmapped registry condition: Extensive-stage Small-cell Lung Cancer","status":"unmapped"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":{"reason":"Conditions lack a therapeutic-area mapping.","status":"unmapped"}},"trial":{"acronym":"IDeate-Lung01","aliases":["IDeate-Lung01","Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)","A Phase 2, Multicenter, Randomized, Open-label Study of Ifinatamab Deruxtecan (I-DXd), a B7-H3 Antibody Drug Conjugate (ADC), in Subjects With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) (IDeate-Lung01)"],"brief_title":"Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)","collaborators":["Merck Sharp & Dohme LLC"],"conditions":["Extensive-stage Small-cell Lung Cancer"],"enrollment":{"count":187,"type":"ACTUAL"},"interventions":[{"name":"Ifinatamab Deruxtecan (I-DXd)","synonyms":["DS-7300a"],"type":"DRUG"}],"nct_id":"NCT05280470","official_title":"A Phase 2, Multicenter, Randomized, Open-label Study of Ifinatamab Deruxtecan (I-DXd), a B7-H3 Antibody Drug Conjugate (ADC), in Subjects With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) (IDeate-Lung01)","overall_status":"ACTIVE_NOT_RECRUITING","phase":["PHASE2"],"primary_completion_date":{"date":"2025-03-03","type":"ACTUAL"},"primary_endpoints":[{"description":"ORR was defined as the percentage of participants who achieved a best overall response (BOR) of confirmed Complete Response (CR) or Partial Response (PR), assessed by BICR based on RECIST version 1.1. For all target, non-target, and new lesions, CR was defined as a disappearance of all lesions and PR was defined as at least a 30% decrease in the sum of diameters of all lesions.","measure":"Percentage of Participants With Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) Following Treatment With I-DXd in Participants With Pretreated ES-SCLC","timeFrame":"Up to approximately 36 months"}],"registry_last_updated":"2026-02-25","registry_url":"https://clinicaltrials.gov/study/NCT05280470","short_name":"IDeate-Lung01","short_name_basis":"registry_acronym","sponsor":"Daiichi Sankyo","start_date":{"date":"2022-03-09","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase2","study_ids":[{"id":"DS7300-127","type":"sponsor_study_id"},{"id":"2022-000503-13","type":"eudract_number"},{"domain":"jRCT","id":"2041220019","type":"other"}],"study_type":"INTERVENTIONAL"}}}